Format

Send to

Choose Destination
J Infect Dis. 2017 Nov 15;216(8):966-968. doi: 10.1093/infdis/jix415.

Human Papillomavirus (HPV) Prevalence in Male Adolescents 4 Years After HPV-16/18 Vaccination.

Author information

1
Faculty of Medicine and Life Sciences, Faculty of Social Sciences, University of Tampere.
2
Department of Clinical Microbiology, Skåne University Hospital, Lund.
3
United Medix Laboratories, Helsinki, Finland.
4
Department of Laboratory Medicine, Karolinska Institute, Stockholm, Sweden.

Abstract

We assessed human papillomavirus (HPV) prevalence among HPV-16/18-vaccinated and unvaccinated Finnish male adolescents participating in chlamydia screening 4 years after vaccination with AS04-adjuvanted HPV-16/18 vaccine in 2007-2009. Previously vaccinated (n = 395) or unvaccinated (n = 149) male adolescents were enrolled in 12 municipalities. First-void urine samples were tested for HPV types 6, 11, 16, 18, 31, 33, 35, 45, 51, 52, 56, 58, 59, 66, and 68, and prevalence rates for HPV-16/18, and HPV-11/16/18/31/33/45 were reduced profoundly (0% vs 2.1% [P = .02] and 0.8% vs 5.3 [P = .002], respectively). Overall HPV DNA prevalence was also significantly reduced among HPV-16/18-vaccinated (4.1%) compared with unvaccinated subjects (10.1%) (P = .01). In this post hoc study, a highly significant reduction in HPV prevalence 4 years after vaccination suggests that the bivalent HPV-16/18 vaccine has protective efficacy in men.

KEYWORDS:

HPV; genital infection; male; prevalence; vaccination

PMID:
28968844
DOI:
10.1093/infdis/jix415
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center